SUBSCRIBE
SUBSCRIBE

Nido Biosciences

NEWS
Map of NextGen Class of 2024/BioSpace
Business
NextGen Class of 2024: Top Life Sciences Startups to Watch This Year
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
January 3, 2024
 · 
20 min read
 · 
BioSpace Editorial Staff
Pictured: Jar of money / Adobe Stock, juliasudnits
Drug Development
Lilly-Backed Nido Biosciences Launches with $109M to Target Neurological Diseases
The precision neuroscience startup has notched $109 million in seed, Series A and B financing as it looks to further develop a Phase I candidate to treat a rare X-linked neuromuscular disorder.
May 15, 2023
 · 
1 min read
 · 
Lisa Munger
IN THE PRESS
Press Releases
Nido Biosciences Announces Publication of Collaborative Research Revealing Clinically Meaningful Endpoints for Spinal and Bulbar Muscular Atrophy
December 4, 2024
 · 
3 min read
Press Releases
Nido Biosciences Announces Orphan Drug Designation for Lead Clinical Candidate to Treat Spinal and Bulbar Muscular Atrophy
October 22, 2024
 · 
3 min read
Genetown
Nido Biosciences Presents Clinical Data Supporting the Continued Development of NIDO-361 in SBMA Patients at the 2023 International Kennedy’s Disease Patient Conference
November 5, 2023
 · 
4 min read
AWARDS
  • NextGen Badge - Brighspot Rework_NextGen - Class of 2024.jpg
JOBS